- Conditions
- Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor
- Interventions
- BMN-673, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Pamela Munster
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 18,735
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Antibody Mediated Rejection of Lung Transplant
- Interventions
- Siltuximab, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Saint Lake City, Utah
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Interventions
- Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
- Conditions
- Leukemia-Lymphoma, Adult T-Cell
- Interventions
- Bortezomib, Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide, Raltegravir
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 6
- States / cities
- Miami, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more
- Conditions
- Healthy
- Interventions
- Acoramidis
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Advanced Solid Tumor
- Interventions
- IPN01195
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Grand Rapids, Michigan • Nashville, Tennessee • Dallas, Texas + 2 more
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- AAV2-BDNF Gene Therapy, AAV2-BDNF Gene Therapy
- Genetic · Biological
- Lead sponsor
- Mark Tuszynski
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • Columbus, Ohio
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Ixabepilone, Cisplatin
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • New Brunswick, New Jersey • Hershey, Pennsylvania
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- paclitaxel poliglumex
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst, Pancreatic Neuroendocrine Tumor, Pancreas; Insulinoma, Pancreatic Cyst, Pancreatic Teratoma, Pancreatic Polypeptide Tumor, Pancreatic Vipoma, Pancreatic Cystadenoma, Pancreas Injury, Pancreatic Gastrinoma, Pancreatic Glucagonoma
- Interventions
- Distal Pancreatectomy Sealing Using LTW
- Device
- Lead sponsor
- Laser Tissue Welding, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- hu14.18-IL2 fusion protein
- Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 54
- States / cities
- Little Rock, Arkansas • Duarte, California • La Jolla, California + 44 more
- Conditions
- Advanced Solid Tumor
- Interventions
- 14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24
- Drug
- Lead sponsor
- Affimed GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Boston, Massachusetts
- Conditions
- Advanced Solid Tumor
- Interventions
- CLR457
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee
- Conditions
- Chronic Weight Management
- Interventions
- ASC30 Injection, for subcutaneous use or placebo
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- HIV
- Interventions
- MRI, L-NMMA, Acetylcholine
- Procedure · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I
- Interventions
- Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein
- Other · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, sargramostim, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN
- Interventions
- Pemigatinib, Gemcitabine, Pembrolizumab, Docetaxel, Trastuzumab, Retifanlimab, Cisplatin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 16 more
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Ph-Like Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin, Laboratory Biomarker Analysis, Leucovorin, Mercaptopurine, Methotrexate, Prednisone, Rituximab, Ruxolitinib Phosphate, Vincristine
- Drug · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma
- Interventions
- injection of mouse TYRP2 DNA
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
- Interventions
- BMF-219
- Drug
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Goodyear, Arizona • Encinitas, California • La Jolla, California + 15 more
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8
- Interventions
- Capecitabine, Fluorouracil, Radiation Therapy, Therapeutic Surgical Procedure
- Drug · Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
- Interventions
- TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (givastomig), durvalumab, chemotherapy
- Drug
- Lead sponsor
- I-Mab Biopharma US Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 11
- States / cities
- Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more
- Conditions
- Healthy Women, Female Contraception
- Interventions
- levonorgestrel butanoate (LB) injection
- Biological
- Lead sponsor
- Premier Research
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Davis, California • Denver, Colorado • Boston, Massachusetts + 4 more